Last reviewed · How we verify
NCT05113381
The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of Intraventricular Hemorrhage (IVH)
NA trial testing CerebroFlo™ EVD Catheter in Intraventricular Hemorrhage in 105 participants. Completed in 31 July 2025.
31 July 2025
Quick facts
| Lead sponsor | Integra LifeSciences Corporation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 105 |
| Start date | 15 September 2021 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 10 locations across United States |
Drugs / interventions tested
- CerebroFlo™ EVD Catheter
Conditions studied
- Intraventricular Hemorrhage — all drugs for Intraventricular Hemorrhage →
- Subarachnoid Hemorrhage — all drugs for Subarachnoid Hemorrhage →
Sponsor
Integra LifeSciences Corporation — full company profile →
Who can join
18 and older, any sex, with Intraventricular Hemorrhage or Subarachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary goal of this study is to assess the occurrence of flushing interventions to address occlusions during the treatment of interventricular hemorrhage (spontaneous primary IVH or secondary IVH due to ruptured aneurysm).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05113381
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intraventricular Hemorrhage
Currently open trials in the same condition.
- NCT07273643 — Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With · recruiting
- NCT06814964 — rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage · Phase 1 · recruiting
- NCT06466811 — Prediction of Undesired Obstruction in External Ventricular Drains. · recruiting
- NCT05849077 — Optimization of Saturation Targets And Resuscitation Trial (OptiSTART) · NA · recruiting
- NCT05568264 — Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit · NA · recruiting
Other Integra LifeSciences Corporation trials
Trials by the same sponsor.
- NCT06760611 — Tissue Quality of Integra vs. BTM Treated Burns · withdrawn
- NCT06629506 — MicroMatrix® Flex in Tunneling Wounds · NA · completed
- NCT06453187 — A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers · NA · enrolling by invitation
- NCT06276543 — Bactiseal Catheter Safety Registry Study · recruiting
- NCT06297187 — Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05113381 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Integra LifeSciences Corporation
- Last refreshed: 15 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05113381.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing